Nature & Science
VaxxersVaxxers

Vaxxers

Vaxxers

user-icon

Sarah Gilbert and Catherine Green

The first COVID-19 vaccines were designed and produced in just over two months, leading up to efficacy trials taking an additional seven months. The ChAdOx1 platform was utilized, previously used in influenza and MERS vaccines, aiding in early dosing testing. Scientists at the CBF and the University of Oxford’s CCVTM proceeded cautiously due to the novel virus's uncertainties. Rigorous testing ensured safety and efficacy before public release, completing animal trials successfully before human dosing. Phase I trials started with 1000 volunteers, focusing on safe immune response induction in adults under 55. Phase II expanded to include older adults without preexisting conditions, leading to Phase III trials open to all adults. Two doses twelve weeks apart showed the highest efficacy levels, reducing infection, transmission, and symptoms. Approval of the AZD1222 vaccine by the UK’s MHRA on December 30th, 2020, led to the first dose administered on January 4th, 2021.

clock10 min
bite6 Bite
target Wgląd

O czym to jest?

In the pursuit of halting the COVID-19 virus, the documentary Vaxxers (2021) documents the competition in creating an effective vaccine. Professor Sarah Gilbert and Dr. Catherine Green, hailing from the University of Oxford, provide intriguing and educational perspectives on the development, examination, and production of the Oxford-AstraZeneca vaccine within an unprecedented timeframe. Through their narrative, they share moments of remarkable ingenuity and the challenges encountered throughout the journey.

Streszczenie książki

Professor Sarah Gilbert is Saïd Professor of Vaccinology at the University of Oxford and the co-founder of Vaccitech, a biotechnology company which develops vaccines and immunotherapies. Professor Gilbert specializes in developing vaccines for various viruses, including influenza, and co-developed the Oxford-AstraZeneca COVID-19 vaccine. This is her first book.

The first COVID-19 vaccines were designed and produced in just over two months, leading up to efficacy trials taking an additional seven months. The ChAdOx1 platform was utilized, previously used in influenza and MERS vaccines, aiding in early dosing testing. Scientists at the CBF and the University of Oxford’s CCVTM proceeded cautiously due to the novel virus's uncertainties. Rigorous testing ensured safety and efficacy before public release, completing animal trials successfully before human dosing. Phase I trials started with 1000 volunteers, focusing on safe immune response induction in adults under 55. Phase II expanded to include older adults without preexisting conditions, leading to Phase III trials open to all adults. Two doses twelve weeks apart showed the highest efficacy levels, reducing infection, transmission, and symptoms. Approval of the AZD1222 vaccine by the UK’s MHRA on December 30th, 2020, led to the first dose administered on January 4th, 2021.

Aby przeczytać resztę książki, możesz pobrać Bitely
appstoregoogleplayapp gallery
Wszystkie kęsy
bite6 Bites

Behind the Breakthrough: Years of Vaccine Preparation

1
logo

Building Vaccines Faster: Lessons from Outbreaks

2
logo

Blueprints for a Pandemic: Rapid Vaccine Innovation

3
logo

Racing Against Time: The 65-Day Vaccine Breakthrough

4
logo

Scaling Vaccines: How Oxford Met Global Demand

5
logo

Rapid Innovation: The Race to Develop AZD1222

6
logo

Powiązane książki

mailbox-icon

Chcesz kontynuować naukę?

Nie przegap aktualizacji z ekscytującego wszechświata Bitely!

Logo
appstoregoogleplay
app gallery

Śledź nas w mediach społecznościowych

tiktokxinstagramyoutubelinkedinfacebook
© 2025 Bitely. Wszelkie prawa zastrzeżone.